Askgene Pharma Inc.

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Amgen Inc.

Jiangsu Aosaikang Ph

Yuefeng Lu

Jian-Feng Lu

Kurt Shanebeck

Lan Yang

Lu Li

Lei Liu

Donggou He

Shiwen Zhang

Chunxiao Yu

Chen Yao

Aijun Wang

Pavel V Bondarenko

Douglas Rehder

Joe Zhou

Margaret Ricci

Yuling Zhang

Thomas M Dillon

Fang Xia

Himanshu S Gadgil

Douglas D Banks

Andrew Goetze

Thomas Dillon

Douglas Banks

Pavel Bondarenko

Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

IL-21 prodrugs and methods of use thereof

Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Antibodies and methods for making and using the same

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Angiopoietin 2, VEGF dual antagonists

Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

IL-15 prodrugs and methods of use thereof

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.

Feline erythropoietin receptor agonists

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.

PD-L1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.

Methods for refolding of recombinant antibodies

Growing community of inventors

Newbury Park, CA, United States of America

Yuefeng Lu